Bayer bets big as hemophilia competition hots up

Bayer has announced it is investing €500m in Germany to create new manufacturing capacity for two hemophilia A treatments in its late-stage pipeline. The recombinant Factor VIII products in question are BAY 81-8973 and BAY 94-9027, both of which offer improvements over existing therapies.